Plasma metabolism of third-generation EGFR-TKI treatment in patients with NSCLC
| Title | Plasma metabolism of third-generation EGFR-TKI treatment in patients with NSCLC |
|---|---|
| Description | Advanced EGFR T790M-mutated non-small cell lung cancer (NSCLC) inevitably develops resistance to third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. Metabolic reprogramming support EGFR-TKI resistance, while thorough metabolomics clinical studies are limited. Here, we enrolled 186 NSCLC patients from Phase I and IIa clinical studies and characterized responsive metabolic features of third-generation EGFR-TKI. Our study included locally advanced or metastatic NSCLC patients from the open-label, single-arm, phase I/IIa study of BPI-7711(NCT03386955). Tumor diagnosis was confirmed by histology or cytology, with EGFR-sensitive mutations (including Exon19Deletion, L858R, G719X, L861QandS768I). |
| Organism | Homo sapiens |
| Data Type | Other Type of Metabolome Data |
| Data Accessibility | Open-access |
| BioProject | PRJCA018003 |
| Release Date | 2024-07-10 |
| Submitter | Yuankai Shi (syuankaipumc@126.com) |
| Organization | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission Date | 2024-07-01 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006787-01 | BPI-7711.zip | 3 | Other Type of Metabolome Data | 3.5 MB | rar | 0 |